Lonza is investing to further expand bioconjugation capabilities at its Visp (CH) site. The expansion adds two production suites to the existing conjugation facility providing development and manufacturing infrastructure for clinical and commercial supply. In addition, an extension to lab space will double the analytical and process development capacity. The new capacity is expected to be fully operational for customers from 1H22.   The 1500m2 expansion adds 30% additional capacity for clinica...